SIVEC BIOTECHNOLOGIES, INC.

Windsor, CO · Founded 2022 · CIK 0002085969 · Biotech · Private

Non-immunogenic engineered bacteria that deliver short hairpin RNA to mucosal cells to trigger RNA interference against influenza virus

sivecbiotechnologies.com →
Grants
$7.0M
7 awards
Sector median: 1
Raised
$3.3M
1 Form D · Sep 2025
13 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues$293,142
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues$293,142
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform$1,028,842
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform$3,048,652
Federal grantDepartment of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform$1,019,722
Federal grantDepartment of Health and Human Services · Phase I · A large-capacity bacterial platform for the production and targeted delivery of gene editing systems$286,081
Federal grantDepartment of Health and Human Services · Phase II · Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform$1,000,088
Private capital raisedForm D · SEC$3,299,994
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2516Prosetta Biosciences Inc.—$31M
2517Metselex, Incorporated——
2518Radionetics Oncology—$54M
2519SIVEC BIOTECHNOLOGIES, INC.—$3.3M
2520MOUNTAIN VALLEY MD INC.—$18M
2521Botanix Pharmaceuticals Ltd.—$20M
2522Quantum Simulation Technologies, Inc.—$7.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Richard Freed IIIDirector
  • Sibylle HauserDirector
  • Lyndsey LinkeDirector · Executive Officer
  • Darcy MoraDirector · Executive Officer
  • David SherrisDirector

Patents

USPTO · 0 granted of 3
  • Chimeric Invasin Systemapplication
  • Bacterial Delivery Of Antibodies, Antibody Derivatives, And Polypeptides To Eukaryotic Cellsapplication
  • Chimeric Invasin Systemapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.